Targeted Diagnostics Boreal Genomics focuses on circulating tumor DNA in plasma to monitor tumor evolution, presenting an opportunity to position OnTarget as a companion diagnostic tool to guide therapy choices and support real-time treatment decisions for oncology teams.

Research-Use Opportunity The OnTarget assay is available as a research-use service, suggesting a potential sales path through research labs and clinical trial sites seeking advanced mutation detection that surpasses conventional methods.

Small Team, Big Reach With a lean employee base and $25M in funding, Boreal may prioritize scalable partnerships, CRO collaborations, and outsourced service arrangements to accelerate product adoption while maintaining cost efficiency.

Cloud and Data Stack Existing tech footprint including AWS, WordPress, and modern web tooling indicates readiness for cloud-based data handling, client portals, and streamlined service delivery, enabling upsell of data management and analytics capabilities.

Funding Leverage Significant external funding combined with sub-$1M revenue signals a growth phase with investment in partnerships, joint development, and grant-aligned programs to expand market reach and accelerate commercialization.